Background: Alcohol-dependent liver transplantation (LT) patients who resume alcohol consumption are at risk for a number of alcohol-related problems including liver injury and liver failure. Post-LT patients are strongly advised to remain abstinent. However, we do not know how well this population complies due to a lack of valid methods (self-report and/or biomarkers) to identify alcohol use. Studies suggest as many as 50% resume alcohol use within 5 years. Phosphatidylethanol (PEth) is a new cell-membrane phospholipid biomarker to identify alcohol use in the past 28 days. This prospective study followed 213 LT recipients at 2 U.S. liver transplant centers.
O VER THE LAST 10 years, 15% of all liver transplants in the United States have been provided to patients with a history of alcohol use disorder (AUD), with most of these patients having a primary diagnosis of alcohol-associated liver disease (ALD). Patients who are alcohol dependent who receive a liver transplant agree to stop alcohol use for the remainder of their life (Lucey, 2014) . Typically, as part of the pretransplant evaluation, transplant programs undertake careful screening of risk factors for posttransplant drinking, with the goal of selecting patients with an acceptable prognosis for long-term abstinence from alcohol. Despite the efforts of transplant programs to discriminate in favor of patients with a low risk of alcohol relapse, prospective studies suggest that up to 50% of these highly selected patients with AUD will use alcohol in the first 5 years after transplant, and 20% will resume harmful drinking (DiMartini et al., 2006 (DiMartini et al., , 2010 .
The relationship of alcohol use to clinical outcomes in posttransplant patients is complex. There are multiple factors associated with the documented increase in 5-to 10-year mortality rates for patients with ALD who return to heavy drinking patterns. Pageaux and colleagues (2003) followed a sample of 128 liver transplantation (LT) subjects for a mean follow-up of 53.8 months with 21% resuming heavy drinking. Of the 7 deaths that occurred in the heavy drinking group, 3 died as a direct of their resumption of alcohol use. Faure and colleagues (2012) reported that of 441 liver transplant patients (206 subjects had ALD as primary indication for transplantation) persistent alcohol use occurred in 43.7% patients with primary indication ALD, and 24.3% in non-ALD patients. Survival was 49% at 10 years for patients with excessive alcohol relapse, compared to 75% who did not resume drinking. The majority of deaths were related to liver failure, cancer, and cardiovascular events.
The largest long-term outcome study to date was conducted on behalf of the European Liver Transplant Center with a sample of 9,988 patients who received a liver transplant from 1988 to 2005 (Burra et al., 2010) . While patients with a primary diagnosis of ALD had improved 5-year survival compared to patients with hepatitis induced liver disease, the differences reversed at 10 years in patients who relapsed. Causes of death include higher rates of cancer and cardiovascular disease, which the authors of the European study suggesting tobacco use as the causal factor in many of these deaths. The effects of noncompliance with immunosuppressive medication, poor follow-up, genetics, and other comorbid disorders also complicate our understanding of the assumed mechanistic role of alcohol use on adverse outcome in the posttransplant period.
Assuming the identification and treatment of any alcohol use in liver transplant patients is the norm, there are a number of alcohol biomarkers in current use to supplement and confirm patient and family member self-report alcohol use. These include blood alcohol concentration, gamma glutamyl transpeptidase (GGT), and carbohydrate-deficient transferrin (CDT). All of these markers, however, have significant clinical limitations, and none are considered standard of care in transplant centers. For example, the half-life of blood alcohol levels is too short. GGT is an indirect marker of alcohol use and is primary marker for liver inflammation by dozens of drugs, diseases, and infections. Another marker in current use and FDA approved is CDT. While it can be falsely elevated in female recipients and patients with liver disease (Fleming et al., 2004) , it can be of some help in healthy subjects. While no alcohol marker is considered standard of care in transplant centers (Lucey, personal communication, December 1, 2016) , phosphatidylethanol (PEth) offers many advantages over other biomarkers and is the subject of this report.
A study reported by Wurst and colleagues (2010) at 3 settings in Europe, in a sample of 57 alcohol-dependent patients during detoxification, reported the following sensitivitiesPEth 100%, mean corpuscular volume 40%, GGT 73%, CDT 69%. A recent systematic review of 58 studies and meta-analysis of 12 by Veil and colleagues (2012) found that PEth was a sensitive and specific alcohol biomarker. Stewart and colleagues (2014) reported high sensitivity and specificity in a sample of 212 drinking patients with liver disease who had PEth levels >8 ng/ml.
The goal of the study was to determine the frequency of a positive PEth level in a sample of liver transplant patients with a history of alcohol dependence and a non-alcoholdependent control sample. Second, we compared selfreported drinking, and physician assessment of return to drinking with PEth levels. To the best of our knowledge, there have been no previous reported PEth studies in a large sample of postliver transplant patients. Previous work in the posttransplant population has been limited to other biomarkers such as GGT, CDT, and ethylglucuronide (Etg) (Staufer et al., 2011) .
MATERIALS AND METHODS
We conducted a prospective study of LT recipients at 2 U.S. transplant centers located in Chicago, Illinois, and Madison, Wisconsin. The primary aim of the study was to assess the clinical utility of PEth as an indicator of recent drinking by LT recipients. The study enrolled a convenience sample of 151 LT recipients with a history of alcohol dependence prior to their transplant and a control sample of 62 recipients with no history of an AUD. The study was conducted from 2012 to 2015 and was approved by the Institutional Review Boards at the University of Wisconsin, Madison, and Northwestern University Feinberg School of Medicine.
The primary inclusion criterion was a history of LT, 1 year or more before study entry. Alcohol use in the past 30 days was assessed using the traditional calendar time line follow back method developed by Sobell and Sobell (1992) . Research staff asked each subject about use of alcohol during each study visit, by using reminder cues such as weekend activities, special events, holidays, and family activities to minimize recall bias. Patients were told the information was confidential and their responses would not be shared with any clinical members of the research team, nor with the transplant program personnel. Additional variables of interest transcribed from the pretransplant evaluation included underlying diagnosis of liver disease, gender, age, race, history of using tobacco, or illicit drugs. In addition to the baseline interview and PEth tests subjects were expected to participate in a 6-and 12-month followup interview and PEth. There was variable success in obtaining follow-up samples due to driving distance from the clinic, comorbid medical problems, and transportation challenges.
The laboratory procedure for PEth analysis used dried blood spot samples from finger picks. Specimens were analyzed at United States Drug Testing Lab (USDTL) in Chicago Illinois using a previously published method (Faller et al., 2011; Gnann et al., 2009; Nalesso et al., 2011; Zheng et al., 2011) . PEth has been found to be stable as dried sample for more than 28 days (Bakhiereva et al., 2015; Kummer et al., 2016) . Three standard blood spot punches (3.1 mm) are prepared for each dried human blood spot specimen, calibrator, and control. The punches are extracted with methanol (1 ml), evaporated under a stream of nitrogen, and the residues are reconstituted in 0.5 ml of mobile phase A (20% 2 mM ammonium acetate: 58% acetonitrile: 22% isopropanol). Separation is achieved with an Agilent Zorbax Eclipse Plus (50 mm 9 2.1 mm, 1.8 mm particle size; Wilmington, DE) C-8 column held at 30°C using an Agilent 6460 liquid chromatography-tandem mass spectrometry as the detector. The chemical name for PETh is 1-palmitoyl-2-oleoylsn-glycero-3-phosphoethanol. The method monitors a single isomer of PEth (palmitoyl/oleoyl), which is the most prevalent PEth species. The laboratory reports levels of the PEth 16:0/18:1 isoenzyme (Jones et al., 2011) . The limit of detection is 2 ng/ml, the limit of quantitation is 8 ng/ml, and the assay is linear up to 800 ng/ml. For the purpose of this study, a positive PEth test is defined as 8 ng/ml or above. Stewart and colleagues' (2014) work showed that a PEth level of 8 ng/ml had a sensitivity (79%) for any reported alcohol use and 98% for 4 or more drinks per day.
The data were entered at each transplant research team site into a Research Electronic Data Capture (REDCap) database while maintaining a back-up hard copy of the research interview. Data collection and management were completed using REDCap tools hosted at each site (Harris et al., 2009) . REDCap is a secure, web-based application designed to support electronic data capture for research studies. The data were cleaned, and data discrepancies were resolved using the back-up hard copies. The analysis was limited to descriptive statistics. We elected to only report the baseline level of alcohol use (see Table 2 ) as the 6-and 12-month levels were similar in subjects who participate in the follow-up tests. We reported all patients who had a positive PEth level at baseline, 6 or 12 months. While most patients with a positive test did so at baseline, there were some who only had a positive test at 6 and/or 12 months. In Table 3 , we included all patients with a positive test even if the test was only positive at 1 time point. We did not conduct sensitivity and specificity analyses of PETh in this sample due to extreme minimization of alcohol use in this population and a literature base of studies that have established a PETh specificity of 100% and sensitivity of 90% or better in heavy drinking populations (Stewart et al., 2014; Veil et al., 2012) . Table 1 , the sample consisted of 213 patients who were more than 1-year post-LT. The majority of the sample lived in Wisconsin or Illinois. There were more males with an average age of 59 and more African Americans in the alcohol-dependent group. Of the 151 alcoholdependent subjects, 13 had other primary causes for liver failure such as hepatitis C viral infection. There were also 8 patients in the control group, who did not meet criteria for alcohol dependence at the time of transplant, who had evidence of alcohol-related disease and cirrhosis after LT. They were placed in the control group for this study based on pre-LT evaluation by an addiction medicine specialist. Table 2 lists self-reported drinking in the 2 groups. As noted, only 14.5% of the controls and 8.6% of alcoholdependent subjects reported use of alcohol at baseline. Among the subjects who reported use of alcohol at baseline, modest amounts of consumption were typical. Only 6 subjects reported drinking more than 6 drinks in the past 30 days. At the extreme end of the spectrum of alcohol use, 2 alcohol-dependent subjects reported they had 6 or more days of drinking in the past 30 days. Table 3 reports the frequency of a positive PEth testing in the sample. In the control group, we observed 13 subjects with a positive PEth test, of which only 3 reported recent alcohol use. In the alcohol-dependent group, we observed a total of 44 positive PEth tests. Only 8 of these 44 subjects admitted they used alcohol in the past 30 days. The mean PEth level varied by group with the 10 positive controls, who did not report recent alcohol use, with the lowest mean PEth level of 17.4 (SD = 9.2) ng/ml and the alcohol-dependent group who reported drinking with the highest mean level of 169 (226.3 SD) ng/ml.
RESULTS

As noted in
We also asked each subject's post-LT physician whether they thought that the individual subject had drunk alcohol recently. These data were collected by medical record reviews. Recent alcohol use was reported on 12 of the subjects with an even distribution of subjects in the control and alcohol-dependent groups. There was no significant correlation between physician medical record data on either selfreported subject alcohol use or PEth levels.
DISCUSSION
First discovered by Alling and colleagues (1984) , PEth is a unique phospholipid formed from phosphatidylcholine present in the membranes of red blood cells. Phospholipase D normally converts phosphatidylcholine to phosphatidic acid. Human red blood cells do not have the enzymatic machinery to efficiently degrade PEth, causing the accumulation of PEth in the cellular membranes following exposure to ethanol (EtOH) (Gustavsson and Alling, 1987) . The natural decomposition of PEth results in a slow elimination, with a half-life of approximately 4 days in adults and PEth detectable in blood for up to 28 days following the last drinking episodes (Wurst et al., 2010) . PEth has been shown to be a sensitive and specific marker of repeated intake of high amounts of alcohol (Veil et al., 2012) , with some evidence for the correlation between alcohol intake and concentration of PEth in blood PEth is produced as soon as alcohol is consumed and is detectable for 24 hours after a single drinking episode of >4 standard drinks.
Research suggests that PEth is 100% specific and detects more than 90% of moderate-to-heavy drinkers (Veil et al., 2012) . Moreover, PEth can remain elevated for up to 28 days after the last drink with repeated episodes of drinking. In 1 recent study, PEth was detectable in 93% of subjects consuming an average of 2 or more drinks per day. PEth can be measured on a blood spot collected on dried blood spot filter paper cards. Using this method, the blood sample is stable at room temperature for more than 28 days (Bakhiereva et al., 2015) . Thus, PEth, when measured using a sensitive liquid chromatography-tandem mass spectrometry assay (Jones et al., 2011) , is a sensitive indicator of moderate alcohol consumption (Kechagias et al., 2015; Stewart et al., 2009 Stewart et al., , 2014 .
In their 2014 article, colleagues (2014, p. 1709) found that "in subjects with quantifiable PEth, the relationship between PEth concentration and alcohol use did not depend on gender, age, or liver disease severity" and that their "results suggest that the validity of PEth remains high regardless of age, gender and liver disease severity." In this study at the limit of quantitation (PEth 20 ng/ml), PEth was 73% sensitive and 96% specific for any drinking in the past month. The subjects who reported 30-day abstinence but with quantifiable PEth either reported heavy drinking within the past 6 weeks or medical record data that suggested underreported drinking.
In the absence of a gold standard, there remains some question on potential false-positive PEth levels as has been found with indirect markers such as CDT. The issue of PEth formation in the absence of recent EtOH intake or formation by other factors has been studied extensively in animal, in vitro red blood cell exposure and clinical studies. None of these studies have found any PEth formation in the absence of EtOH. Phospholipase D is unable to convert phosphatidylcholine into PEth without the presence of EtOH (Frohman et al., 1999; Gustavsson and Alling, 1987; Gustavsson and Hansson, 1990; Gustavsson et al., 1991; Kobayashi and Kanfer, 1987; Lundqvist et al., 1994; Metz and Dunlop, 1991; Stewart et al., 2014) . There remain additional questions, however, regarding PEth levels and duration of detection that may be affected by individual metabolism of EtOH, genetic differences, and unknown mechanisms.
The clinical implications of light and social drinking in posttransplant patients are unclear particularly in patients where ALD was not the primary reason for the liver transplant. As noted in our study, a significant number of controls who received a liver transplant for viral hepatitis, hepatic cancer, drug toxicity, etc., had positive PEth levels. As not a single study had demonstrated a clinical benefit to alcohol use following LT, it seems obvious that it is not worth the risk to the individual or society. However, one can make the argument from the other side of the argument that until we demonstrate measurable effects to 1 to 2 drinks a few times a month why should physician encourage total abstinence. With the advent of biosensors on the back of watches (continuous use; https://www.nih.gov/. . ./niaaa-selects-winnersits-wearable-alcohol-biosensor-challenge), PEth (28 days), and EtG (past 90 days; Staufer et al., 2011) in nails, a longterm study of posttransplant patients to address this question is now possible and can potentially establish the relative risk of varying levels of alcohol use in this population (1.0 or no risk? 1.5? 2.0?). We also need more data on tobacco use associated with alcohol use and its relationship to laryngeal and esophageal malignancies that are a major cause of death in ALT transplant patients.
The use of biomarkers to confirm abstinent self-report both before and after liver transplant is more than a clinical issue. While the direct effects of social drinking on the longterm survival of transplant patients remain unclear, except in the case of the patient who resumes dependent patterns of alcohol use (Dumortier et al., 2015; Rice et al., 2013) , physicians have a social contract to do everything possible to minimize loss of any transplant-even one. Someday if livers are available to all people who need one, the recommendation for complete abstinence could be revisited in patients who receive a transplant for ALD.
The most striking observation in the present study was that PEth revealed an unexpected frequency of clandestine drinking. Borrowing from a previous study of treatment of AUD in the setting of LT, we adopted a study model to encourage a candid admission of alcohol use by the study subject, by creating a firewall between the study responses and the transplant program (Weinrieb et al., 2011) . Despite this protection of the confidences that our subjects might have shared, many patients denied drinking while having positive PEth. Indeed, the extent of covert alcohol use was surprising, with 29% of alcohol-dependent patients having a positive PEth, the great majority of whom (91.4%) reported being abstinent from alcohol. At the same time, the managing physician usually was unaware of the patients drinking, emphasizing the limitations of physician inquiry as a means of identifying the at-risk post-LT population.
The drinking behavior described in this prospective study occurred after the LT recipient was advised by their treating physician to stop drinking alcohol. This begs 2 questions: (i) Why are these patients not abstinent? and (ii) Why are they hiding their drinking? Regarding the first question, one possibility is that the patients had not received a clear message to stop drinking, or had poor recollection of that advice, as has been reported (Tang et al., 1998) . This possibility reinforces the need for patients to receive explicit directions regarding the expectation for long-term abstinence. Moreover, our results suggest that important changes in health care policy could focus on including an "abstinence contract" in the pre-LT evaluation process. However, we think there is a greater likelihood that alcohol-dependent patients in our study were aware that they need to remain abstinent.
Regarding the second question about patients hiding their drinking, we know that LT recipients with a history of alcohol dependency who return to alcohol use are often reticent about their drinking, either out of shame or for fear of disapproval by the transplant team, or fearful of the loss of privileges such as access to retransplantation were it to become indicated. This issue has been called the "risk of candor" (Weinrieb et al., 2000) . We are less clear as to why nondependent LT recipients should deny alcohol use, other than to speculate that this behavior reflects a fear of a punitive action by the transplant team.
Our study was not designed to describe the consequences of clandestine alcohol use in LT recipients. The value of an effective biomarker is that it provides an opportunity to open a dialog with the patient, to explore their reasons for drinking, and to encourage entry into treatment for AUD. We are not able to say whether the subgroups of dependent and nondependent covert drinkers progressed to overt and/or harmful drinking. Similarly, we cannot determine whether we would have been successful in guiding our covert drinkers into treatment for addiction, nor whether such an intervention would be accompanied by successful cessation of alcohol use.
In summary, our study suggests that PEth is a useful biomarker to identify mild-to-moderate alcohol use by LT recipients and that drinking behavior is often hidden from the patient's transplant team. PEth is quickly becoming the standard alcohol use detection test of drunk driver programs, professional impairment programs, alcohol treatment studies, and medication interactions in clinical care. While some medical insurance companies do not reimburse for alcohol biomarkers, the test is <$100. PEth levels are a fraction of the cost for many transplant-related laboratory tests. Future studies will be directed at linking identification of covert drinking with strategies to establish abstinence.
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